Teva Pharmaceutical Industries Ltd (TEVA)
$9.29 0.12 (1.28%)
19:57 EDT TEVA Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 9.46B
PE Ratio -0.59
Volume (Avg. Vol.) 4.61M
Day's Range 9.22 - 9.53
52-Week Range 6.25 - 13.76
Dividend & Yield 0.07 (0.78%)
TEVA Stock Predictions, Articles, and Teva Pharmaceutical Industries Ltd News
- From InvestorPlace
- From the Web
The stock market may have forgotten about these seven undervalued stocks, but you can pick them up now on the cheap.
Investors have many cheap stocks to buy, using widely-followed metrics or by looking at those lacking institutional interest.
The devastation of the coronavirus was the last straw for the Trump administration, prompting an aggressive approach to U.S.-China relations. Here are some of the top companies to invest in to account for this foreign policy shift.
Due to the disjointed fundamentals, many investors were caught off guard with this current bull market. However, there are cheap stocks to buy that are still available.
Several healthcare stocks have jumped higher based off the coronavirus pandemic. But these nine companies have a longer upside pathway.
As the coronavirus pandemic worsens, stable but boring recession-proof stocks to buy are suddenly in vogue. Here are the nine picks that might ride this black swan even to profitability.
By Thomas Niel
TEVA stock was a great contrarian play last fall. With opioid liabilities hanging like an anvil over the company, shares were priced for disaster. More than doubling from their 2019 lows, I wouldn't say Teva shares are now "priced to perfection". But, the current share price may be pricing in much of the upside. Bottom Line? Consider TEVA stock a hold. With markets facing volatility, a better entry point could spring up down the road.
The forward price-earnings ratio of Teva stock is only 5, and its trailing price/sales ratio is 0.8. With Teva's financial situation in control and given the company's multiple growth drivers, those valuation metrics are quite low.
TEVA stock is about as far from a feel-good investment as you can get. But the underlying generics drug industry is still an important one, making shares a tough contrarian opportunity.
Teva stock rose 9% after a positive earnings report. But after $3 billion in cost-cutting, investors may be looking for additional revenue.
Here's your complete guide on which stocks to buy, depending on who wins the 2020 U.S. Presidential Election.
It increasingly appears that Teva stock is in the early stages of going from multi-year loser to multi-year winner.
Teva Pharmaceuticals (TEVA) earnings for the pharmaceutical company's fourth quarter of 2019 have TEVA stock taking off on Wednesday.
Looking for a stock that will double or triple in 2020? These 10 lottery stocks have a realistic opportunity to do just that.
With plans to capture 25% of the market, the nod from the FDA should help reduce the sting of having to abandon its planned use of Ajovy for cluster headaches, a move that was dropped last year after a failed phase 3 trial, which gave Eli Lilly the market to itself.
Teva Pharmaceuticals may look interesting after its recent surge, but the near-term outlook of TEVA stock is somewhat murky.
Teva can handle its debt and deal with its liability from the opioid tragedy. And Teva stock has multiple, positive catalysts.
Teva New Case Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva Pharmaceutical Industries Limited To Contact The Firm
From Market News Video
Investors in Teva Pharmaceutical Industries Ltd (TEVA) saw new options become available today, for the June 2021 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 246 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..
Navellier RatingsPowered by Portfolio Grader